Again, no significant adverse events were reported
We offer both standard methylcobalamin B12 and custom B12 complex options that may include additional supportive nutrients based on your individual needs assessment
The published data shows meaningful but modest fat loss in clinical conditions, approximately 1 to 2 kg of additional fat loss over 12 weeks compared to placebo at 1 mg/day
Some GI adjustment (mild nausea, fullness) is normal and passes within 2-4 weeks
[22] [23] Baseline assessment should be considered before initiating tirzepatide in high-risk patients, including those over 65 years of age, individuals with pre-existing gastrointestinal disorders, patients on concurrent metformin or acid-suppressing medications, and those following restrictive diets
Regulatory Status and Safety Takeaway FDA Status: IGF-1 LR3 is not approved by the FDA for human therapeutic use and is highly restricted